EGFR and dysplasia: Previous experimental studies of colitis showed that EGFR may regulate inflammatory cytokine production (Lu et al., 2014; El Mahdy et al., 2023), and that the EGFR inhibitor, erlotinib, protects from chronic inflammation and development of dysplasia (Pagán et al., 2011).